Kornimate/medical-research-clean huggingface dataset:
yinhu qingwen granule in the treatment of viral pneumonia

Conditions: Viral Pneumonia

Summary: this is a non-randomized single arm clinical study to observe the effect of yinhu qingwen granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

preliminary pharmacodynamic and toxicological studies can show that yinhu qingwen granule has a certain effect on pneumonia caused by various viruses, and its safety is good. this study aims to observe the effect of yinhu qingwen granule in the relief of fever and improvement of related-symptoms of patients with viral pneumonia.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of viral pneumonia; * clinical diagnosis of shi-du-yun-jie zheng (damp stagnation syndrome) according to chinese medicine, including fever,cough,sore throat,stuffy chest,irritability and thirst,short yellow urine,constipation or loose stool,thick and greasy yellow coating,and slippery pulse; * chest ct showed signs of acute exudative pneumonia in the lungs; * over 18 years old, regardless of gender, voluntarily signed an informed consent form; * those who were hospitalized and were accompanied by fever (body temperature ≥37.3℃) and respiratory tract symptoms like cough or dyspnea, when they were enrolled. exclusion criteria: * patients that are susceptible to sensitivity or known to be allergic to the study drug; * patients whose white blood cell count ≥12×10\^9 or neutrophil percentage ≥80%; * patients whose weight is less than 40 kg; * patients with respiratory failure or need mechanical ventilation; * patients with shock; * patients required to be in icu monitoring and treatment; * patients participated in other clinical trials within 1 month; * patients with known renal impairment; * patients with any of the following laboratory parameter abnormalities during the screening period or within 24 hours before screening: alt or ast level\> 5 times the upper limit of normal range (uln) or-alt or ast level \> 3 times uln and total bilirubin level\> 2 times uln; * patients with immune system diseases and long-term use of immunosuppressive agents; * pregnant or breastfeeding women, or who have a positive pregnancy test during the screening period, or plan to become pregnant within 3 months after the study treatment.
a phase 1 study testing cp-675,206 in combination with gemcitabine in patients with previously untreated, advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to determine the safety and tolerability of different doses of cp-675,206 in combination with gemcitabine and to determine the maximum dose of cp-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.


Eligibility criteria:
inclusion criteria: * patients with metastatic pancreatic cancer * patient must have adequate bone marrow, liver and kidney function * patient must have an eastern cooperative oncology group (ecog) performance score of 0 or 1 * chemotherapy naive * inoperable pancreatic cancer exclusion criteria: * patient must not have received prior systemic therapy for pancreatic cancer * patient must not have previously received anti-ctla4 therapy * history of chronic inflammatory or autoimmune disease

Keywords: interventional dose-finding
nursing intervention for hiv regime adherence among people with serious mental illness (smi)

Conditions: HIV; Mental Illness

Summary: the purpose of this research study is to investigate how nurses can best help people with serious mental illnesses (smi) follow their hiv treatment plans.

there is concern that hiv positive smi persons may be a greater risk for poor treatment adherence, increasing risk for poorer outcomes and development of treatment resistance virus, and also placing others at greater risk. involvement of advance practice nurses has been previously shown to improve outcomes for persons with hiv/aids.

Eligibility criteria:
inclusion criteria: * diagnosis of serious mental illness; hiv positive exclusion criteria: * none

Keywords: hiv mental illness
efficacy of dextromethorphan-bupropion versus ssris in the treatment of major depressive disorder

Conditions: Major Depressive Disorder (MDD)

Summary: the study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard ssri therapy in adult patients with major depressive disorder. participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an ssri (e.g., sertraline or escitalopram). treatment will last for 6 weeks, with assessments at baseline and study completion. the primary outcome will be the remission rate measured by a validated depression rating scale. secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.


Eligibility criteria:
inclusion criteria: diagnosed with major depressive disorder (mdd) per dsm-5 criteria. baseline depression score indicating moderate to severe depression ability to provide informed consent willing to comply with study requirements exclusion criteria: history of bipolar disorder, schizophrenia, or other psychotic disorders current substance use disorder (within past 6 months) active suicidal ideation requiring urgent intervention pregnancy or breastfeeding known hypersensitivity to study medications
effects of remote ischemic preconditioning on peripheral blood biomarkers in healthy adults (eminent)

Conditions: Ischemic Preconditioning

Summary: the aim of this study is to investigate the effects of remote ischaemic preconditioning on the peripheral blood characteristics of healthy adults and to explore the possible mechanisms for improving ischaemia/reperfusion injury and its protective effects on the cardiovascular system.

this study plans to recruit 60 healthy volunteers, who will be randomly divided into a high-frequency group and a low-frequency group. the high-frequency remote ischemic preconditioning (ripc) group will undergo ripc training continuously for seven days, twice daily, with each session consisting of four cycles of 5 minutes of ischemia followed by 5 minutes of reperfusion. the low-frequency ripc group will follow the same cycle and compression pattern but will train only once a day. biological samples and physiological indicators will be collected from participants on the day just before the start of ischemic preconditioning training, as well as on the 7th and 14th days following the start of the training. these samples will be analyzed to identify the differences in blood components between groups and at different time points before and after ripc. the study aims to investigate the effects of different training frequencies of ripc on the characteristics of peripheral blood in healthy adults, as well as the changes in the peripheral blood characteristics of the participants before and after the training.

Eligibility criteria:
inclusion criteria: * aged 18 to 45 years; * be in good health; * consent to participate in the clinical trial and sign the informed consent form. exclusion criteria: * abnormal results in biochemical checks and physiological indicators. * cardiovascular and cerebrovascular diseases: hypertension, coronary heart disease, congenital heart disease, cerebrovascular alterations, etc. * endocrine diseases: diabetes, thyroid disorders, etc. * hematologic diseases: anemia, paroxysmal hemoglobinuria, primary thrombocytosis, etc. * infectious diseases: hepatitis b, hepatitis c, syphilis, etc. * cancer. * neurological and psychiatric disorders. * vascular diseases: peripheral vascular disease, raynaud's syndrome, thromboembolic diseases. * major trauma or surgery within the last six months. * pregnant or breastfeeding women. * upper limbs unsuitable for compression treatment: history of upper limb surgery, presence of tissue damage and limb deformity, and concomitant hemorrhagic diseases. * recent circumstances that may affect results: blood donors within the last month, any medication taken within the last month, fever within the last week, women within their menstrual cycle or within 7 days before the start of menstruation. * patients who refuse to sign the informed consent form for participation in this study.

Keywords: remote ischemic preconditioning peripheral blood healthy adults
efficacy of an educational school-based intervention to reduce prevalence of obesity in childhood-edal-2

Conditions: Childhood Obesity

Summary: our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. as such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (hpa) on the prevalence of obesity.

initial pupil enrollment and continued for 3 years.

Eligibility criteria:
inclusion criteria: * in the intervention group, all children of the selected classroom are exposed to the intervention. * the data a will collected on all the children, but only the data from individuals (and their parents) who provided informed consent are included in the final analyses. * name, gender, date and place of birth are recorded at the start of the program, while weight, height, body mass index (bmi) and waist circumference variables (identified set of anthropometric measures) are recorded in each of the 3 academic years of the study. exclusion criteria: * no adequate age * lack of inclusion criteria
regulatory post-marketing surveillance study for tetraxim™

Conditions: Diphtheria; Tetanus; Pertussis; Poliomyelitis

Summary: the purpose of this study is to assess the safety of tetraxim™ administered in routine clinical practice according to korea food and drug administration notification no. 2009-46 "basic standard for reexamination of new drug" based on the pharmaceutical law in korea.

primary vaccination will be administered from 2 months and booster vaccination from age 4 to 6 years.

Eligibility criteria:
inclusion criteria: * subjects who are 2 months or more of age (as indicated in the currently approved local product labeling) and who are given the study vaccine at least one dose or more, during a routine health-care visit, as primary immunization or booster immunization for the prevention of diphtheria, tetanus, pertussis, poliomyelitis. * written informed consent obtained from the subject's parents/legal representative.

Keywords: diphtheria tetanus pertussis poliomyelitis tetraxim™
intervention trial to increase meaning in work and reduce burnout

Conditions: Burnout, Professional

Summary: collegiality is a one of the great virtues of physician-hood. mutual support from colleagues to help deal with the challenges of being a physician has long helped physicians manage the stress related to practicing medicine and helped physicians derive meaning from their work. unfortunately, increased productivity expectations and other changes to the practice of medicine over the last several decades have decreased the time physicians have to interact with colleagues and eroded the fabric of collegiality. recent studies suggest burnout affects nearly half of u.s. physicians at any given point in time and has substantial personal and professional consequences. the steps organizations can take to promote collegiality are unknown. the goal of the present study is to evaluate the ability of an organizational intervention to encourage collegiality, shared experience, connectedness, and mutual support. this study builds on two prior intervention studies directed by the mayo clinic department of medicine program on physician well-being, the first focusing on a small group facilitated well-being curriculum and the second focusing on individual electronic tasks to prompt positive reflection and gratitude.


Eligibility criteria:
inclusion criteria: * senior associate consultants and consultants in the mayo clinic department of medicine will be eligible for this study. exclusion criteria: * none beyond inclusion criteria.

Keywords: well-being burnout
safety and efficacy of local anesthesia in emergency inguinal hernia surgery

Conditions: Anesthesia; Incarcerated Inguinal Hernia

Summary: this prospective randomized is designed to evaluate the safety and efficacy of hernia repairs using local anesthesia compared with those using general anesthesia for patients with incarcerated hernia.

the outcome parameters measured included intraoperative conditions, postoperative conditions and long-term follow-up conditions.

Eligibility criteria:
inclusion criteria: 1. age 18-70 years 2. primary inguinal hernia 3. asa i-ii 4. clinical diagnosis of incarcerated hernia 5. randomly select patch agreed by patients and family members exclusion criteria: 1. severe organ dysfunction 2. no-tolerate anesthesia 3. no-suitable for operation 4. spirit disease patients 5. automatically exit

Keywords: incarcerated anesthesia hernia
intravenous tnk vs tpa for ais treatment on msu,a prospective multicenter rct

Conditions: Intravenous; Thrombosis; Acute Ischemic Stroke

Summary: acute ischemic stroke is one of the devastating diseases that increase hospitalization, disabilities, and deaths worldwide. current treatment with intravenous thrombolytic agent can help reduce disabilities and improve quality of life. intravenous alteplase is proven benefit and now used as the first-line drug for acute ischemic stroke with symptom onset less than 4.5 hours and without contraindications. tenecteplase, a genetically engineered tissue-type plasminogen activator, has been questioned to treat acute ischemic stroke instead of intravenous alteplase. tenecteplase has more advantages over alteplase including higher fibrin specificity, longer half-life and easier to administer as a single intravenous bolus. the efficacy and safety of intravenous tenecteplase has been studied recently. in 2017, a phase 3 randomized open-label, blinded trial (nor-test) 6 showed that there were no significant differences in efficacy and safety between tenecteplase and alteplase in mild stroke patients. a study in 2020, in the setting of acute large artery occlusion, tenecteplase resulted in a better 90-day neurological outcome and provided more benefits in reperfusion before endovascular thrombectomy10. regarding safety concerns, tenecteplase showed no significant higher incidence of intracerebral hemorrhage. administration, tenecteplase might be better in the setting of the case on mobile stroke units. assuming, earlier reperfusion by thrombolytic drug may have improved patient's neurologic outcomes. we aim to compare the efficacy and safety between intravenous tenecteplase and alteplase in acute ischemic stroke patients given on mobile stroke units within 4.5 hours after symptom onset.


Eligibility criteria:
inclusion criteria: * diagnosed as acute ischemic stroke within 4.5 hr of symptom onset * age \> 18 years old * no contraindication for thrombolytic drug * informed consent from patients exclusion criteria: * diagnosed as acute ischemic stroke with more than 4.5 hours of symptom onset or uncontained onset * have contraindication for thrombolytic drugs

Keywords: acute ischemic stroke mobile stroke unit intravenous tenecteplase
us inhaled insulin dose titration study

Conditions: Diabetes Mellitus, Type 2

Summary: this study will examine how to dose exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. this study should show that a large number of patients enrolled in the study can reach the target hemoglobin a1c levels (7% or less) that have been set by the american diabetes association (ada). target goals should be achieved by adjusting the exubera dose either weekly or twice weekly. patients will also receive nutritional counseling and diabetes education as part of the study.


Eligibility criteria:
inclusion criteria: * male and female, age \>= 18 years and \<= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin a1c 7.5-10% * currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones) exclusion criteria: * type 1 diabetes * smoking within the past 6 months or significant pulmonary diseases
the metformin in coronary artery bypass graft (cabg) (metcab) trial

Conditions: Cardiovascular Disease; Ischemic Heart Disease

Summary: rationale: in patients with a myocardial infarction, occlusion of a coronary artery induces myocardial ischemia and cell death. if untreated, the area of myocardium exposed to this interruption in blood supply, will largely become necrotic. the only way to limit final infarct size, is timely reperfusion of the occluded artery. paradoxically, however, reperfusion itself can also damage myocardial tissue and contribute to the final infarct size ("reperfusion injury"). also during coronary artery bypass grafting (cabg), the myocardium is exposed to ischemia and reperfusion, which will induce cell death. indeed, postoperatively, the plasma concentration of troponin i, a marker of cardiac necrosis, is increased, and associated with adverse outcome. the anti-hyperglycaemic drug metformin has been shown in preclinical studies to be able to reduce ischemia-reperfusion injury and to limit myocardial infarct size. moreover, metformin therapy improves cardiovascular prognosis in patients with diabetes mellitus. paradoxically, in patients with diabetes, current practice is to temporarily stop metformin before major surgery for the presumed risk of lactic acidosis, which is a rare complication of metformin. however, here is no evidence that this practice benefits the patient. the investigators hypothesize that pretreatment with metformin can reduce myocardial injury in patients undergoing elective cabg surgery


Eligibility criteria:
inclusion criteria: * acceptation for cabg with or without concomitant valve surgery * informed consent * age ≥ 18 years exclusion criteria: * diabetes mellitus * renal dysfunction (mdrd \< 60 ml/min) * elevated liver enzymes (alat \> 3 times upper limit of reference range) * treatment with dipyridamole or xanthine derivatives * recent myocardial infarction (\<2 weeks before inclusion) * off-pump surgery

Keywords: ischemia reperfusion injury cabg metformin hs-troponin-i
urinary proteomic assessment of ovarian malignancy and disease progression

Conditions: Ovarian Cancer (OvCa)

Summary: the goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. the main questions it aims to answer are: 1. what is the difference in urinary protein composition between patients with ovarian cancer and those without it? 2. can these differences in urinary protein composition aid in the diagnosis of ovarian cancer? 3. are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer? 4. can urinary protein markers be used for disease surveillance in ovarian cancer patients?


Eligibility criteria:
inclusion criteria: * female patients in the gynecological ward for surgical treatment. * initial diagnosis of "pelvic mass" or "malignant ascites" may be considered as ovarian cancer; or the initial diagnosis of "ovarian cyst", "hydrosalpinx", "uterine fibroids" or "uterine adenomyosis" are considered as gynecological non-malignant diseases. * over 18 years of age. * voluntary participation and signing of informed consent. exclusion criteria: * study participants with a prior history of malignant tumors. * study participants with prior chronic kidney disease or renal insufficiency. * study participants who have received or are receiving treatment for primary disease. * study participants whose pathological diagnosis was not clear. any patient should be excluded from the study if: * study participants withdraw informed consent and request withdrawal. * study participants were unable to provide a qualified urine sample. * there are situations in which the researcher considers it necessary to withdraw from the study.
lung ultrasound and alveolar recruitment in mechanically ventilated infants

Conditions: Pulmonary Atelectasis

Summary: investigators hypothesized that lung ultrasound-assisted recruitment maneuver would be beneficial in mechanically ventilated infants compared to those who did not receive lung ultrasound and alveolar recruitment maneuver.


Eligibility criteria:
inclusion criteria: * minor surgery less than 2 hours under general anesthesia * mechanically ventilated after endotracheal intubation exclusion criteria: * history of surgery on the lungs * laparoscopic surgery * abnormal preoperative chest radiograph findings including atelectasis, pneumothorax, pleural effusion, and pneumonia * considered inappropriate by the investigator

Keywords: ultrasonography infant perioperative period general anesthesia
treatment of mild enteropathy celiac disease

Conditions: Celiac Disease

Summary: the main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (marsh i-ii) in the small-bowel mucosa. the investigators hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. if this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.

the current diagnostic criteria of celiac disease require small-bowel mucosal villous atrophy with crypt hyperplasia (marsh iii). however, the mucosal damage develops gradually and the patients may have clinical symptoms and endomysial antibodies before the development of villous atrophy. the main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (marsh i-ii) in the small-bowel mucosa. we hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. if this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.

Eligibility criteria:
inclusion criteria: * celiac disease suspicion * positive endomysial antibodies * at least marsh i -type small-bowel mucosal lesion exclusion criteria: * earlier celiac disease diagnosis * consuming oral corticosteroids or immune suppressants

Keywords: celiac disease endomysial antibodies mild enteropathy treatment gluten-free diet